2023 Fiscal Year Final Research Report

Development of New Treatment Method for Epithelioid Sarcoma by BNCT

Research Project

PDF

Project/Area Number	19K09599
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56020:Orthopedics-related
Research Institution	Kobe University
Principal Investigator	Fujimoto Takuya 神戸大学, 医学研究科, 医学研究員 (00397811)
Co-Investigator(Kenkyū-buntansha)	鈴木実京都大学, 複合原子力科学研究所, 教授 (00319724) 河本旭哉神戸大学, 医学部附属病院国際がん医療・研究センター, 医学研究員 (30420558) 原仁美神戸大学, 医学部附属病院, 助教 (40437489) 安藤徹神戸学院大学, 薬学部, 助教 (50639226)
Project Period (FY)	2019-04-01 – 2024-03-31
Keywords	類上皮肉腫 / ホウ素中性子捕捉療法 / BNCT / 担がん動物モデル / 細胞株 / VA-ES-BJ
Outline of Final Research Achievements	Epithelioid sarcoma (ES) is an extremely rare sarcoma that predominates in young adults. Because it is not sensitive to anticancer drugs and radiation therapy, wide surgical excision is the basis of treatment. Therefore, in this study, BNCT was performed with the use of human ES (VA-ES-BJ cell line)-bearing nude mice, and its antitumor effect was examined. After the tumor transplanted into the thigh grew, animals were divided into 3 groups of A, B, and C. In group C (BNCT), after intravenous administration of BPA, and in group B without administration of BPA, only the tumor of both groups was irradiated with epithermal neutrons. The tumor tissue was removed and histological examination was performed 14 days after irradiation. Histological examination revealed destroyed tumor cells only in group C. For the first time, it was clear that ES regressed with only one irradiation by BNCT in this study. Therefore, a new treatment method for ES by BNCT is expected to be developed in future.
Free Research Field	骨軟部腫瘍
Academic Significance and Societal Importance of the Research Achievements	類上皮肉腫(ES)は、極めて稀な悪性軟部腫瘍である。しかし、通常の癌治療は効果なく腫瘍切除が治療の基本となるため、常に新たな治療法が求められている。ここで、近年、腫瘍細胞のみにホウ素製剤(BPA)を送達し、対外照射により腫瘍細胞内で熱中性子線とホウ素の核分裂反応を生じさせ腫瘍を選択的に死滅させるホウ素中性子捕捉療法(BNCT)の研究が進んでいる。そこで、ESに対するBNCTの適応を目指して、新たにヒト由来のES細胞株VA-ES-BJを用いた担がん動物モデルを作成しBNCTの治療効果を検討した。そして、ESに対するBNCTの抗腫瘍効果を初めて確認し、BNCTによる新たな治療方法の可能性を示した。